After 10 years of follow-up, 60% of the breast cancers were screen-detected, 31% were diagnosed with a stage 2 or later cancer, 86% were invasive, 86% were estrogen-receptor (ER)-positive, 72% were progesterone-receptor (PR)-positive, and 14% were human epidermal growth factor receptor 2 (HER2)-positive, as shown in Table A1. This evidence concerns the gene ERBB2 and breast carcinoma.